{"id":30367,"date":"2025-01-21T15:45:00","date_gmt":"2025-01-21T14:45:00","guid":{"rendered":"https:\/\/ggba.swiss\/?p=30367"},"modified":"2025-02-05T10:29:25","modified_gmt":"2025-02-05T09:29:25","slug":"brainscape-medical-makes-strides-in-long-term-brain-monitoring","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/","title":{"rendered":"BrainScape Medical makes strides in long-term brain monitoring"},"content":{"rendered":"\n

Founded in late 2024, BrainScape Medical<\/a> aims to revolutionize the diagnosis, monitoring, and treatment of neurological disorders. Through an exclusive license agreement with the Wyss Center for Bio and Neuro Engineering<\/a>, BrainScape has acquired the Epios\u00ae technology (now called Brainscape Platform), a cutting-edge implantable device developed in Geneva. This innovation addresses the challenges of capturing continuous, long-term brain activity data\u2014critical for managing complex conditions like epilepsy and dementia, which affect millions worldwide.<\/p>\n\n\n\n

The BrainScape Platform combines monitoring and therapeutic intervention into a single, minimally invasive system. By providing real-time insights and enabling neurofeedback and stimulation, the technology aims to improve outcomes for patients while setting a new standard in personalized care.<\/p>\n\n\n\n

The first-in-human trial of the Brainscape Platform demonstrated the device\u2019s safety and efficacy. Conducted on eight patients over nine days, the study successfully recorded long-term EEG signals with full head coverage. Published in leading medical journals, these results highlight the BrainScape Platform as a groundbreaking solution for brain activity detection, paving the way for expanded clinical applications and personalized therapeutic interventions.<\/p>\n\n\n\n

Advancing neurology through strategic leadership FDA recognition and Swiss innovation support<\/strong><\/p>\n\n\n\n

In the company\u2019s press release, Dr. Erwin B\u00f6ttinger, Director of the Wyss Center, emphasized the collaboration\u2019s potential: \u201cThe strides made by BrainScape Medical reflect our commitment to translating innovative research into real-world solutions that improve lives.\u201d<\/p>\n\n\n\n

The BrainScape Platform has received the U.S. FDA\u2019s Breakthrough Device Designation for its potential to address unmet needs in managing pharmacoresistant epilepsy and infrequent seizure episodes. This recognition will streamline regulatory processes, expediting patient access to the technology in the U.S. market.<\/p>\n\n\n\n

To support its growth, BrainScape Medical has appointed Dr. Laura Johnson as CEO. With over 20 years of medtech leadership experience, Dr. Johnson brings a vision for advancing the neuro-therapeutics market. She aims to lead BrainScape through a Series A funding round, support FDA approval, and explore new applications for the BrainScape Platform.<\/p>\n\n\n\n

Supported by GGBa<\/a> and the Office Cantonal de l’\u00c9conomie et de l’Innovation (OCEI<\/a>) in its establishment, BrainScape Medical is headquartered at the Campus Biotech<\/a> in Geneva, leveraging the region\u2019s robust innovation ecosystem. With its technology and a clear roadmap for growth, the company is on track to transform the treatment of neurological disorders and improve the standard of care for millions of people worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"

Geneva-based BrainScape Medical, a newly incorporated company specializing in neuromonitoring and neurostimulation technologies, has announced several milestones, including new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.<\/p>\n","protected":false},"author":6,"featured_media":30368,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[890,918,963,926,940],"class_list":["post-30367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-healthcare","tag-investment","tag-medical-devices","tag-medtech","tag-neuroscience"],"acf":[],"yoast_head":"\nBrainScape Medical makes strides in long-term brain monitoring<\/title>\n<meta name=\"description\" content=\"BrainScape Medical has announced a new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BrainScape Medical makes strides in long-term brain monitoring\" \/>\n<meta property=\"og:description\" content=\"BrainScape Medical has announced a new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-21T14:45:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-05T09:29:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Brainscape-Medical-Geneva-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"BrainScape Medical makes strides in long-term brain monitoring\",\"datePublished\":\"2025-01-21T14:45:00+00:00\",\"dateModified\":\"2025-02-05T09:29:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/\"},\"wordCount\":395,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Brainscape-Medical-Geneva-1180x811-1.jpeg\",\"keywords\":[\"Healthcare\",\"Investment\",\"Medical Devices\",\"Medtech\",\"Neuroscience\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/\",\"url\":\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/\",\"name\":\"BrainScape Medical makes strides in long-term brain monitoring\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Brainscape-Medical-Geneva-1180x811-1.jpeg\",\"datePublished\":\"2025-01-21T14:45:00+00:00\",\"dateModified\":\"2025-02-05T09:29:25+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"BrainScape Medical has announced a new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Brainscape-Medical-Geneva-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Brainscape-Medical-Geneva-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"BrainScape Medical\u2019s Platform combines cutting-edge brain monitoring with therapeutic interventions, offering new hope for managing neurological disorders through personalized care. | \u00a9 BrainScape Medical\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BrainScape Medical makes strides in long-term brain monitoring\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BrainScape Medical makes strides in long-term brain monitoring","description":"BrainScape Medical has announced a new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/","og_locale":"en_US","og_type":"article","og_title":"BrainScape Medical makes strides in long-term brain monitoring","og_description":"BrainScape Medical has announced a new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.","og_url":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-01-21T14:45:00+00:00","article_modified_time":"2025-02-05T09:29:25+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Brainscape-Medical-Geneva-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"BrainScape Medical makes strides in long-term brain monitoring","datePublished":"2025-01-21T14:45:00+00:00","dateModified":"2025-02-05T09:29:25+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/"},"wordCount":395,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Brainscape-Medical-Geneva-1180x811-1.jpeg","keywords":["Healthcare","Investment","Medical Devices","Medtech","Neuroscience"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/","url":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/","name":"BrainScape Medical makes strides in long-term brain monitoring","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Brainscape-Medical-Geneva-1180x811-1.jpeg","datePublished":"2025-01-21T14:45:00+00:00","dateModified":"2025-02-05T09:29:25+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"BrainScape Medical has announced a new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Brainscape-Medical-Geneva-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Brainscape-Medical-Geneva-1180x811-1.jpeg","width":1180,"height":811,"caption":"BrainScape Medical\u2019s Platform combines cutting-edge brain monitoring with therapeutic interventions, offering new hope for managing neurological disorders through personalized care. | \u00a9 BrainScape Medical"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/brainscape-medical-makes-strides-in-long-term-brain-monitoring\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"BrainScape Medical makes strides in long-term brain monitoring"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/30367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=30367"}],"version-history":[{"count":6,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/30367\/revisions"}],"predecessor-version":[{"id":30833,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/30367\/revisions\/30833"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/30368"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=30367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=30367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=30367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}